We discover new treatments and develop pharmaceutical products for rare diseases, by repurposing already marketed drugs.
This is achieved by a revolutionary computational engine based on AI together with the medical expertise offered by the leading experts in the field provided by disease organizations such as patient societies with which purposeful works hand in hand.
By repurposing existing drugs purposeful cuts decisively the risks of drug development achieving faster and cheaper pharmaceutical treatments to meet the patients’ medical needs, where the high costs of traditional drug development would make it infeasible.
Purposeful aims to develop pharmaceutical products all the way to Market Authorization. Within a very short period of time our pipeline has been populated by candidates which have already passed successfully in vitro and in vivo evaluation, while our first clinical trial is about to start
AI engine
In the big data era, AI and machine learning offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. Purposeful’s engine in accelerating the finding of repurposed drugs for treating rare and challenging diseases in which the underlying disease mechanisms remain poorly understood and the potential for multiple distinct disease drivers exists.
We discover novel targets which are Phase II/ III ready.
We offer rapid and cost-effective solutions for therapeutic development.
Data sources
As the volume of available data is increasing, the opportunities for using these resources to drug repurposing are exciting. Big data comes with inherent limitations and biases, for that reason maintaining rigour and critical analysis is the key to optimising data use.
Expert opinion
Purposeful’s engine is placing a special weight on experts’ advice in order to find something that matters to people with special needs. A milestone to our workflow are the invaluable collaborations with patient groups and organisations that we seek to establish.
Model informed drug discovery and development (MID3)
Purposeful is using state of the art Modelling and Simulation (M&S) approaches to guide the translation from preclinical to clinical and the clinical development of its candidates in an integrated quantitative framework which has been termed as MID3.
Save resources
Drug repurposing succeeds in reducing development timelines and overall costs, for that AI approaches are not just formidable but are also necessary.